Cabaletta Bio Receives FDA Orphan Drug Designation for Innovative Autoimmune Disease Therapy
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to its investigational therapy, CABA-201. This designation …
Cabaletta Bio Receives FDA Orphan Drug Designation for Innovative Autoimmune Disease Therapy Read More